All In Biotech

NDA 205410 · Eton

Hemangeol

Propranolol Hydrochloride · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 14, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

392

63 Phase 3, 46 recruiting

FAERS reports

15,795

8,000 serious, 1,476 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2026.

HEMANGEOL oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. HEMANGEOL oral solution is a beta-adrenergic blocker indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 14, 2014 Original approval · Type 5 - New Formulation or New Manufacturer OrphanReviewLetterLabel
1 products under this application
  • HEMANGEOL · PROPRANOLOL HYDROCHLORIDE 4.28MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Propranolol" as an intervention, any sponsor and status, largest first.

All 392 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use3,538
  • drug ineffective1,369
  • product use issue1,177
  • product use in unapproved indication987
  • nausea930
  • inappropriate schedule of product administration914
  • diarrhoea851
  • product administered to patient of inappropriate age832
  • headache799
  • fatigue796
  • toxicity to various agents695
  • vomiting635

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200499
2005162
2006127
200798
200879
2009153
2010174
2011164
2012203
2013141
2014146
2015164
2016296
2017299
2018524
2019639
20201,084
2021897
20221,990
20232,089
20242,693
20252,017
20261,557

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,504 on PubMed

Sponsor: Eton

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.